Browse the corpus

Glimepiride is a medication used in the management and treatment of type 2 diabetes mellitus. It is in the sulfonylurea class of drugs. This activity outlines the indications, mechanism of action, and contraindications for glimepiride as a valuable agent in managing type 2 diabetes mellitus. This activity will also highlight the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, monitoring, relevant interactions) pertinent for interprofessional healthcare team members managing patients with type 2 diabetes mellitus and related conditions. Objectives: Identify the mechanism of action of glimepiride. Describe the possible adverse effects of glimepiride. Review appropriate monitoring methods for patients on glimepiride, including management of complications of treatment. Explain the importance of collaboration and communication amongst the interprofessional team and patients to improve patient outcomes when receiving glimepiride therapy. Access free multiple choice questions on this topic.

In cases of overdose of sulfonylureas such as glimepiride, hypoglycemia can occur. It is essential to recognize the signs and symptoms of hypoglycemia, which can fall into the following two categories: Autonomic symptoms such as tremor, palpitations, nausea, tachycardia, diaphoresis, and anxiety Neuroglycopenic symptoms such as confusion, fatigue, headache, drowsiness, coma, and seizures. Rapid recognition and reversal of hypoglycemia are essential in improving prognosis in those that have overdosed on glimepiride.[13] Initial management is intravenous dextrose; however, this is quickly switched to octreotide (long-acting somatostatin analog) as many patients will have sufficient pancreatic function to stimulate endogenous insulin production in response leading to a cycle of dextrose infusion and rebound hypoglycemia. Additionally, activated charcoal should be given as soon as possible for decontamination. In an emergency or pre-hospital setting, intramuscular injections of glucagon can temporarily increase blood glucose via physiological glycogenolysis and gluconeogenesis. However, as glucagon stimulates insulin release, this is not recommended.[14]

Managing type 2 diabetes mellitus involves an interprofessional healthcare team approach involving various healthcare team members, including but not limited to the endocrinologist, family/primary care clinician (MDs, DOs, PAs, NPs), diabetes specialist nurse, podiatrist, and pharmacist. Its management involves the utilization of drugs that control blood glucose, which include glimepiride. Glimepiride is a second-line, FDA-approved drug to be used either in combination with metformin or as a monotherapy. Sulfonylureas augment and increase insulin release from the pancreas and, although effective, poses a threat to patient safety if used inappropriately. Sufficient communication is essential in delivering optimal care to patients, including providing information in aspects such as time and frequency of administration and associated sick day rules. Through a coordinated interprofessional team effort, diabetes management, including the use of glimepiride, can achieve better patient outcomes and limit the potential for therapeutic failure or adverse events. [Level 5]